:: ::
Back to the articles list Back to browse issues page
Future of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?
Mona Salimi
Abstract:  

Triple negative breast cancer (TNBC): challenges and solutions via the immune cells

TNBC is one of the most complicated types of breast cancer to treat. It is generally diagnosed based on the absence of three receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) and is thus defined as a triple negative. TNBC is often more aggressive with lower survival rates than other forms of breast cancer; however, the outlook depends on the stage of diagnosis. This type of breast cancer cannot attract potent anti-cancer and hormone drugs due to the lack of surface proteins, so patients diagnosed with the disease have to rely almost exclusively on chemotherapy. In recent years, immunotherapy has gained attention, as a developing option, to treat a subset of cancers... 

Full-Text [PDF 474 kb]      
Type of Study: Study Break | Subject: Related Fields
Add your comments about this article
Your username or Email:

Write the security code in the box >



PMID: 29101913


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Salimi M. Future of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?. IBJ. 2017;
URL: http://ibj.pasteur.ac.ir/article-1-2240-en.html
Back to the articles list Back to browse issues page
Persian site map - English site map - Created in 0.147 seconds with 863 queries by yektaweb 3525